Payment overview · 2025
General Payments
$186.17
10 reported records · 7 companies
Healthcare provider profile · identity verified
Gary James Robinson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LUMBERTON, NC · NPI 1457416778
Verified facts
What the public records show
CMS Open Payments records show Gary James Robinson, M.D. received $186.17 in general payments during 2025 across 10 reported records.
Lilly USA, LLC accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $67.69 | 36.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.49 | 21.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.77 | 9.6% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.89 | 9.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.32 | 8.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.28 | 7.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.73 | 7.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $186.17 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $67.69 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.00 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.49 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 410 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 341 | 86 |
| Metformin Hcl | Metformin Hcl | 224 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 220 | 59 |
| Gabapentin | Gabapentin | 217 | 56 |
| Furosemide | Furosemide | 196 | 49 |
| Lisinopril | Lisinopril | 193 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 190 | 44 |
| Ozempic | Semaglutide | 188 | 33 |
| Omeprazole | Omeprazole | 185 | 44 |
| Alprazolam | Alprazolam | 184 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 37 |
| Carvedilol | Carvedilol | 137 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 137 | 35 |
| Famotidine | Famotidine | 131 | 30 |
| Potassium Chloride | Potassium Chloride | 128 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 31 |
| Montelukast Sodium | Montelukast Sodium | 115 | 28 |
| Tramadol Hcl | Tramadol Hcl | 114 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 20 |
| Losartan Potassium | Losartan Potassium | 112 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 27 |
| Azithromycin | Azithromycin | 108 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 24 |
| Simvastatin | Simvastatin | 103 | 25 |
| Trazodone Hcl | Trazodone Hcl | 103 | 24 |
| Prednisone | Prednisone | 102 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 20 |
| Sertraline Hcl | Sertraline Hcl | 94 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 33 |
| Glimepiride | Glimepiride | 76 | 15 |
| Allopurinol | Allopurinol | 74 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 15 |
| Linzess | Linaclotide | 72 | 20 |
| Eliquis | Apixaban | 70 | 17 |
| Metformin Hcl Er | Metformin Hcl | 67 | 19 |
| Glipizide | Glipizide | 61 | 17 |
| Jardiance | Empagliflozin | 61 | 16 |
| Ezetimibe | Ezetimibe | 60 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | suppressed |
| Meloxicam | Meloxicam | 56 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | suppressed |
| Glipizide Er | Glipizide | 53 | 11 |
| Clonazepam | Clonazepam | 52 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 49 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 16 |
| Ondansetron Odt | Ondansetron | 46 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | suppressed |
| Ibuprofen | Ibuprofen | 43 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 19 |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Tradjenta | Linagliptin | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Lorazepam | Lorazepam | 39 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | 11 |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Fluconazole | Fluconazole | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Topiramate | Topiramate | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $186.17 · 10 records | Lilly USA, LLC | AREXVY, Cologuard Collection Kit, INSPIRE, MOUNJARO, PURIFIED CORTROPHIN GEL, SHINGRIX, XIFAXAN, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error